Common Contracts

EX-10.2 3 dex102.htm PATENT LICENSE AGREEMENT Execution Version PATENT LICENSE AGREEMENT PATENT LICENSE AGREEMENT (“Agreement”), dated January 20, 2009 (the “Effective Date”), by and between PANACOS PHARMACEUTICALS, INC., a Delaware corporation...

Patent License Agreement • May 5th, 2020 • Delaware

• Contract Type
  Patent License Agreement
• Filed
  May 5th, 2020
• Jurisdiction
  Delaware

WHEREAS, pursuant to an Asset Purchase Agreement dated as of January 20, 2009, by and between Panacos and Myriad (“Purchase Agreement”), Myriad acquired certain assets from Panacos used or which Myriad intends to use in connection with the development (preclinical and clinical), manufacture and commercialization of 3-O-(3’,3’-dimethylsuccinyl) betulinic acid and salts and solvates thereof, and polymorphs thereof (“Bevirimat”);

PATENT LICENSE AGREEMENT

Patent License Agreement • January 23rd, 2009 • Panacos Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware

• Contract Type
  Patent License Agreement
• Filed
  January 23rd, 2009
• Company
  Panacos Pharmaceuticals, Inc.
• Industry
  Biological products, (no disgnostic substances)
• Jurisdiction
  Delaware

WHEREAS, pursuant to an Asset Purchase Agreement dated as of January 20, 2009, by and between Panacos and Myriad (“Purchase Agreement”), Myriad acquired certain assets from Panacos used or which Myriad intends to use in connection with the development (preclinical and clinical), manufacture and commercialization of 3-O-(3’,3’-dimethylsuccinyl) betulinic acid and salts and solvates thereof, and polymorphs thereof (“Bevirimat”);